- Home
- GBR vs SBFM Comparison
GBR vs SBFM Comparison
Compare GBR & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBR
- SBFM
- Stock Information
- Founded
- GBR 1978
- SBFM 2006
- Country
- GBR United States
- SBFM United States
- Employees
- GBR N/A
- SBFM N/A
- Industry
- GBR Oil & Gas Production
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- GBR Energy
- SBFM Health Care
- Exchange
- GBR Nasdaq
- SBFM Nasdaq
- Market Cap
- GBR 7.0M
- SBFM 6.6M
- IPO Year
- GBR N/A
- SBFM N/A
- Fundamental
- Price
- GBR $1.05
- SBFM $1.54
- Analyst Decision
- GBR
- SBFM Strong Buy
- Analyst Count
- GBR 0
- SBFM 1
- Target Price
- GBR N/A
- SBFM $15.00
- AVG Volume (30 Days)
- GBR 257.7K
- SBFM 188.9K
- Earning Date
- GBR 08-12-2025
- SBFM 08-15-2025
- Dividend Yield
- GBR N/A
- SBFM N/A
- EPS Growth
- GBR N/A
- SBFM N/A
- EPS
- GBR N/A
- SBFM N/A
- Revenue
- GBR $148,000.00
- SBFM $36,234,578.00
- Revenue This Year
- GBR N/A
- SBFM $192.48
- Revenue Next Year
- GBR N/A
- SBFM N/A
- P/E Ratio
- GBR N/A
- SBFM N/A
- Revenue Growth
- GBR 3.50
- SBFM 35.51
- 52 Week Low
- GBR $0.67
- SBFM $1.17
- 52 Week High
- GBR $1.79
- SBFM $7.18
- Technical
- Relative Strength Index (RSI)
- GBR 46.95
- SBFM 51.91
- Support Level
- GBR $0.84
- SBFM $1.43
- Resistance Level
- GBR $1.23
- SBFM $1.61
- Average True Range (ATR)
- GBR 0.08
- SBFM 0.11
- MACD
- GBR -0.03
- SBFM 0.01
- Stochastic Oscillator
- GBR 3.36
- SBFM 41.67
About GBR New Concept Energy Inc
New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations. It operates in one segment, which is real estate rental.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.